Return to Today's science sparks archives

2016-07-01

Fig 1. Granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor β chain (GM-CSFRβ) signaling is critical for survival, fungal clearance, and lung integrity during Aspergillus fumigatus challenge.

Fig 1. Granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor β chain (GM-CSFRβ) signaling is critical for survival, fungal clearance, and lung integrity during Aspergillus fumigatus challenge.
  • Kasahara S, Jhingran A, Dhingra S, Salem A, Cramer RA, Hohl TM

  • J Infect Dis. 2016 Apr 15;213(8):1289-98.
Open Access button

2016-07-05

Fig 1. Recurrent LM along a prior surgical scar, 7 years following initial treatment. The initial lesion was microinvasive with a Breslow depth of 0.1 mm. The recurrence had a depth of 0.8 mm.

Fig 1. Recurrent LM along a prior surgical scar, 7 years following initial treatment. The initial lesion was microinvasive with a Breslow depth of 0.1 mm. The recurrence had a depth of 0.8 mm.
  • Connolly KL, Nijhawan RI, Dusza SW, Busam KJ, Nehal KS

  • J Am Acad Dermatol. 2016 Jun;74(6):1247-8.

2016-07-06

Fig 3. ADT did not alter the plaque burden but induced plaque necrosis in leuprolide treated mice.

Fig 3. ADT did not alter the plaque burden but induced plaque necrosis in leuprolide treated mice.
  • Knutsson A, Hsiung S, Celik S, Rattik S, Mattisson IY, Wigren M, Scher HI, Nilsson J, Hultgårdh-Nilsson A

  • Sci Rep. 2016 May 18;6:26220.
Open Access button

2016-07-07

Fig 1. Methodology for application of exclusion criteria. Abbreviations: BSI, bloodstream infection; E. faecium, Enterococcus faecium.

Fig 1. Methodology for application of exclusion criteria. Abbreviations: BSI, bloodstream infection; E. faecium, Enterococcus faecium.
  • Shukla BS1, Shelburne S2, Reyes K3, Kamboj M4, Lewis JD5, Rincon SL, Reyes J, Carvajal LP, Panesso D, Sifri CD, Zervos MJ, Pamer EG, Tran TT, Adachi J, Munita JM, Hasbun R, Arias CA

  • Clin Infect Dis. 2016 Jun 15;62(12):1514-20.

2016-07-08

Fig 1. Approach and implications to rating the quality of evidence and strength of recommendations using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology (unrestricted use of this figure granted by the US GRADE Network).

Fig 1. Approach and implications to rating the quality of evidence and strength of recommendations using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology (unrestricted use of this figure granted by the US GRADE Network).
  • Barlam TF, Cosgrove SE, Abbo LM, MacDougall C, Schuetz AN, Septimus EJ, Srinivasan A, Dellit TH, Falck-Ytter YT, Fishman NO, Hamilton CW, Jenkins TC, Lipsett PA, Malani PN, May LS, Moran GJ, Neuhauser MM, Newland JG, Ohl CA, Samore MH, Seo SK, Trivedi KK

  • Clin Infect Dis. 2016 May 15;62(10):1197-202.

2016-07-11

Fig 5. The region encompassing rs55705857 acts as a MYC enhancer and rs55705857-G allele increases this activity.

Fig 5. The region encompassing rs55705857 acts as a MYC enhancer and rs55705857-G allele increases this activity.
  • Oktay Y, Ege Ülgen ÖC, Akyerli CB, Yüksel Ş, Erdemgil Y, Durası İM, Henegariu OI, Nanni EP, Selevsek N, Grossmann J, Erson-Omay EZ

  • Sci Rep. 2016 Jun 10;6:27569.
Open Access button

2016-07-12

Fig 1. In this figure, part of the MET gene is depicted on the left in A. This portion of the gene includes exons 13, 14, and 15, and introns 13 and 14. DNA is transcribed into pre-mRNA, and introns are spliced out (orange triangles) by normal splicing mechanisms.

Fig 1. In this figure, part of the MET gene is depicted on the left in A. This portion of the gene includes exons 13, 14, and 15, and introns 13 and 14. DNA is transcribed into pre-mRNA, and introns are spliced out (orange triangles) by normal splicing mechanisms.
  • Drilon A

  • Clin Cancer Res. 2016 Jun 15;22(12):2832-4.

2016-07-13

Fig 6. Features of Loqs-Sensitive miRNAs.

Fig 6. Features of Loqs-Sensitive miRNAs.
  • Lim MY, Ng AW, Chou Y, Lim TP, Simcox A, Tucker-Kellogg G, Okamura K

  • Cell Rep. 2016 May 24;15(8):1795-808.
Open Access button

2016-07-14

Fig 2. Detected mosaic events on the X chromosome.

Fig 2. Detected mosaic events on the X chromosome.
  • Machiela MJ, Zhou W, Karlins E, Sampson JN, Freedman ND, Yang Q, Hicks B, Dagnall C, Hautman C, Jacobs KB, Abnet CC

  • Nat Commun. 2016 Jun 13;7:11843.
Open Access button

2016-07-15

Fig 1. Fosbretabulin mechanism of action.

Fig 1. Fosbretabulin mechanism of action.
  • Monk BJ, Sill MW, Walker JL, Darus CJ, Sutton G, Tewari KS, Martin LP, Schilder JM, Coleman RL, Balkissoon J, Aghajanian C

  • J Clin Oncol. 2016 Jul 1;34(19):2279-86.

2016-07-18

Fig 1. Polypodium leucotomos (PL) extract’s anti-UV effects.

Fig 1. Polypodium leucotomos (PL) extract’s anti-UV effects.
  • Parrado C, Mascaraque M, Gilaberte Y, Juarranz A, Gonzalez S

  • Int J Mol Sci. 2016 Jun 29;17(7).
Open Access button

2016-07-19

Fig 1. Second generation CAR structure.

Fig 1. Second generation CAR structure.
  • Davila ML, Sadelain M

  • Int J Hematol. 2016 Jul;104(1):6-17.

2016-07-20

Fig 1. Next-generation sequencing for clinical infectious disease diagnostics.

Fig 1. Next-generation sequencing for clinical infectious disease diagnostics.
  • Westblade LF, van Belkum A, Grundhoff A, Weinstock GM, Pamer EG, Pallen MJ, Dunne WM

  • J Clin Microbiol. 2016 Jul;54(7):1686-93.

2016-07-21

Fig 3. Initial changes and resolution of magnetic resonance imaging findings during treatment with nivolumab.

Fig 3. Initial changes and resolution of magnetic resonance imaging findings during treatment with nivolumab.
  • Bouffet E, Larouche V, Campbell BB, Merico D, de Borja R, Aronson M, Durno C, Krueger J, Cabric V, Ramaswamy V, Zhukova N

  • J Clin Oncol. 2016 Jul 1;34(19):2206-11.

2016-07-22

Fig 3. Tertiary structure of Msm0858 and comparison to mammalian p97.

Fig 3. Tertiary structure of Msm0858 and comparison to mammalian p97.
  • Unciuleac MC, Smith PC, Shuman S

  • J Bacteriol. 2016 Apr 28;198(10):1521-33.

2016-07-25

Fig 2. Genetic structure of mcr-1-harboring elements in selected plasmids.

Fig 2. Genetic structure of mcr-1-harboring elements in selected plasmids.
  • Li A, Yang Y, Miao M, Chavda KD, Mediavilla JR, Xie X, Feng P, Tang YW, Kreiswirth BN, Chen L, Du H

  • Antimicrob Agents Chemother. 2016 Jun 20;60(7):4351-4.

2016-07-26

Fig 5. 5-FU Alters Overflow Metabolism In Vivo, and the End Products Can Be Measured in Serum.

Fig 5. 5-FU Alters Overflow Metabolism In Vivo, and the End Products Can Be Measured in Serum.
  • Ser Z, Gao X, Johnson C, Mehrmohamadi M, Liu X, Li S, Locasale JW

  • Cell Rep. 2016 Jun 14;15(11):2367-76.
Open Access button

2016-07-28

Fig 2. Fkh1 interacted with Mph1 through the FHA domain.

Fig 2. Fkh1 interacted with Mph1 through the FHA domain.
  • Dummer AM, Su Z, Cherney R, Choi K, Denu J, Zhao X, Fox CA

  • PLoS Genet. 2016 Jun 3;12(6):e1006094.
Open Access button

2016-07-29

Fig 1. Distribution of PMTB oncologic diagnoses.

Fig 1. Distribution of PMTB oncologic diagnoses.
  • Ortiz MV, Kobos R, Walsh M, Slotkin EK, Roberts S, Berger MF, Hameed M, Solit D, Ladanyi M, Shukla N, Kentsis A

  • Pediatr Blood Cancer. 2016 Aug;63(8):1368-74.

2016-08-01

Fig 2. Strategies for personalized precision immunotherapy.

Fig 2. Strategies for personalized precision immunotherapy.
  • Mandal R, Chan TA

  • Cancer Discov. 2016 Jul;6(7):703-13.

2016-08-02

Fig 2. Systematic Analysis of 166 TFs and 1,309 Drug Perturbation Experiments Identifies Approximately 38,000 Candidate TF-Drug Pairs.

Fig 2. Systematic Analysis of 166 TFs and 1,309 Drug Perturbation Experiments Identifies Approximately 38,000 Candidate TF-Drug Pairs.
  • Gayvert KM, Dardenne E, Cheung C, Boland MR, Lorberbaum T, Wanjala J, Chen Y, Rubin M, Tatonetti NP, Rickman DS, Elemento O

  • Cell Rep. 2016 Jun 14;15(11):2348-56.
Open Access button

2016-08-03

Fig 1. Best percentage change from baseline in sum of the longest diameters of target lesions by PD-L1 TPS.

Fig 1. Best percentage change from baseline in sum of the longest diameters of target lesions by PD-L1 TPS.
  • Chatterjee M, Turner DC, Felip E, Lena H, Cappuzzo F, Horn L, Garon EB, Hui R, Arkenau HT, Gubens MA, Hellmann MD

  • Ann Oncol. 2016 Jul;27(7):1291-8.

2016-08-04

Fig 1. Repertoires of somatic mutations, gene copy number alterations, and mutational signatures in sporadic synchronous endometrioid endometrial carcinomas (EECs) and endometrioid ovarian carcinomas (EOCs).

Fig 1. Repertoires of somatic mutations, gene copy number alterations, and mutational signatures in sporadic synchronous endometrioid endometrial carcinomas (EECs) and endometrioid ovarian carcinomas (EOCs).
  • Schultheis AM, Ng CK, De Filippo MR, Piscuoglio S, Macedo GS, Gatius S, Mies BP, Soslow RA, Lim RS, Viale A, Huberman KH

  • J Natl Cancer Inst. 2016 Feb 1;108(6):djv427.

2016-08-05

Fig 2. Molecular subsets of LCNEC. A, OncoPrint depicting coalterations in selected genes in LCNEC with presence or absence of RB1+TP53 coalteration defining the major SCLC-like and NSCLC-like subsets, respectively, and MEN1 mutations (mut) and low total mutation burden defining carcinoid-like subset.

Fig 2. Molecular subsets of LCNEC. A, OncoPrint depicting coalterations in selected genes in LCNEC with presence or absence of RB1+TP53 coalteration defining the major SCLC-like and NSCLC-like subsets, respectively, and MEN1 mutations (mut) and low total mutation burden defining carcinoid-like subset.
  • Rekhtman N, Pietanza MC, Hellmann MD, Naidoo J, Arora A, Won H, Halpenny DF, Wang H, Tian SK, Litvak AM, Paik PK

  • Clin Cancer Res. 2016 Jul 15;22(14):3618-29.

2016-08-08

Fig 1. A paradigm switch in T cell therapy.

Fig 1. A paradigm switch in T cell therapy.
  • Sadelain M

  • Curr Opin Immunol. 2016 Jun 30;41:68-76.

2016-08-09

Fig 3. Hematoxylin and eosin stain at 4× (A) and 20× (B) magnification.

Fig 3. Hematoxylin and eosin stain at 4× (A) and 20× (B) magnification.
  • Hawkins RB, Rosenberger LH, Swanson JC, Gangemi JJ, McGahren ED

  • Journal of Pediatric Surgery Case Reports. 2016 Jul 31;10:29-31.
Open Access button

2016-08-10

Fig 5. Structure of the N-terminal domain of Ltn1.

Fig 5. Structure of the N-terminal domain of Ltn1.
  • Doamekpor SK, Lee JW, Hepowit NL, Wu C, Charenton C, Leonard M, Bengtson MH, Rajashankar KR, Sachs MS, Lima CD, Joazeiro CA

  • Proc Natl Acad Sci U S A. 2016 Jul 19;113(29):E4151-60.

2016-08-11

Fig 4. Blocking KIR3DL1-h interaction with Bw4-80I rescues natural killer cells (NK cells) from inhibition.

Fig 4. Blocking KIR3DL1-h interaction with Bw4-80I rescues natural killer cells (NK cells) from inhibition.
  • Forlenza CJ, Boudreau JE, Zheng J, Le Luduec JB, Chamberlain E, Heller G, Cheung NK, Hsu KC

  • J Clin Oncol. 2016 Jul 20;34(21):2443-51.

2016-08-12

Fig 8. 6 MV IMRT head and neck.

Fig 8. 6 MV IMRT head and neck.
  • Davidson SE, Cui J, Kry S, Deasy JO, Ibbott GS, Vicic M, White RA, Followill DS

  • Med Phys. 2016 Aug;43(8):4842.

2016-08-15

Fig 3. This lung shows centrilobular emphysema with dropout of alveolar walls surrounding the bronchiole (hematoxylin and eosin stain, original magnification ×4).

Fig 3. This lung shows centrilobular emphysema with dropout of alveolar walls surrounding the bronchiole (hematoxylin and eosin stain, original magnification ×4).
  • Ofran Y, Tallman MS, Rowe JM

  • Blood. 2016 Jul 28;128(4):488-96.

2016-08-16

Fig 6. Network of Proteins Associated with Docetaxel Perturbation of the Cell Cycle.

Fig 6. Network of Proteins Associated with Docetaxel Perturbation of the Cell Cycle.
  • Kusebauch U, Campbell DS, Deutsch EW, Chu CS, Spicer DA, Brusniak MY, Slagel J, Sun Z, Stevens J, Grimes B, Shteynberg D

  • Cell. 2016 Jul 28;166(3):766-78.

2016-08-17

Fig 2. Proportion of patients with hyponatremia, by hyponatremia severity and cancer type.

Fig 2. Proportion of patients with hyponatremia, by hyponatremia severity and cancer type.
  • Castillo JJ, Glezerman IG, Boklage SH, Chiodo J, Tidwell BA, Lamerato LE, Schulman KL

  • BMC Cancer. 2016 Jul 29;16:564.
Open Access button

2016-08-18

Fig 4. Mixed epithelial carcinoma.

Fig 4. Mixed epithelial carcinoma.
  • Thomas S, Hussein Y, Bandyopadhyay S, Cote M, Hassan O, Abdulfatah E, Alosh B, Guan H, Soslow RA, Ali-Fehmi R

  • Arch Pathol Lab Med. 2016 Aug;140(8):836-43.

2016-08-19

Fig 2. Murine liver sinusoidal endothelium accumulated fCNT in vivo.

Fig 2. Murine liver sinusoidal endothelium accumulated fCNT in vivo.
  • Alidori S, Bowman RL, Yarilin D, Romin Y, Barlas A, Mulvey JJ, Fujisawa S, Xu K, Ruggiero A, Riabov V, Thorek DL

  • Nat Commun. 2016 Jul 29;7:12343.
Open Access button

2016-08-23

Fig 1. Waterfall plot of 38 evaluable patients (per protocol population) treated with entinostat.

Fig 1. Waterfall plot of 38 evaluable patients (per protocol population) treated with entinostat.
  • Batlevi CL, Kasamon Y, Bociek RG, Lee P, Gore L, Copeland A, Sorensen R, Ordentlich P, Cruickshank S, Kunkel L, Buglio D

  • Haematologica. 2016 Aug;101(8):968-75.

2016-08-24

Fig 1. Digitalized prostate histopathology.

Fig 1. Digitalized prostate histopathology.
  • Lawrence EM, Warren AY, Priest AN, Barrett T, Goldman DA, Gill AB, Gnanapragasam VJ, Sala E, Gallagher FA

  • PLoS One. 2016 Jul 28;11(7):e0159652.
Open Access button

2016-08-25

Fig 1. Brain MRI with expansile, high T2 signal tumor in the right medial temporal lobe, optic chiasm, optic tracts, hypothalamus, and right parahippocampal region as well as abnormal enhancement in the right medial inferior temporal lobe and right inferior frontal lobe.

Fig 1. Brain MRI with expansile, high T2 signal tumor in the right medial temporal lobe, optic chiasm, optic tracts, hypothalamus, and right parahippocampal region as well as abnormal enhancement in the right medial inferior temporal lobe and right inferior frontal lobe.
  • Mazgaj R, Gerson R, Khakoo Y, Petriccione M, Haque S, Haddad F

  • Psychooncology. 2016 Aug;25(8):994-6.

2016-08-26

Fig 5. Schematic model of a lipidic pore formed by Bak homodimers.

Fig 5. Schematic model of a lipidic pore formed by Bak homodimers.
  • Mandal T, Shin S, Aluvila S, Chen HC, Grieve C, Choe JY, Cheng EH, Hustedt EJ, Oh KJ

  • Sci Rep. 2016 Aug 4;6:30763.
Open Access button

2016-08-29

Fig 10. The WT virus dominates in coinfected animals.

Fig 10. The WT virus dominates in coinfected animals.
  • Saito A, Henning MS, Serrao E, Dubose BN, Teng S, Huang J, Li X, Saito N, Roy SP, Siddiqui MA, Ahn J

  • J Virol. 2016 Jul 11;90(15):6918-35.

2016-08-30

Fig 1. Activity of 14 and the Rv2887 mutations identified in 14-resistant Mtb clones.

Fig 1. Activity of 14 and the Rv2887 mutations identified in 14-resistant Mtb clones.
  • Warrier T, Kapilashrami K, Argyrou A, Ioerger TR, Little D, Murphy KC, Nandakumar M, Park S, Gold B, Mi J, Zhang T

  • Proc Natl Acad Sci U S A. 2016 Aug 2;113(31):E4523-30.

2016-08-31

Fig 3. An example study as a model of combining midostaurin and alloHCT.

Fig 3. An example study as a model of combining midostaurin and alloHCT.
  • Ustun C, Gotlib J, Popat U, Artz A, Litzow M, Reiter A, Nakamura R, Kluin-Nelemans HC, Verstovsek S, Gajewski J, Perales MA

  • Biol Blood Marrow Transplant. 2016 Aug;22(8):1348-56.

2016-09-01

Fig 1. CHEK2*1100delC frequency rates per country in legend are shown with 95% confidence intervals and were calculated using a modification of the empirical Bayes approach proposed by Clayton and Kaldor, as described in the methods.

Fig 1. CHEK2*1100delC frequency rates per country in legend are shown with 95% confidence intervals and were calculated using a modification of the empirical Bayes approach proposed by Clayton and Kaldor, as described in the methods.
  • Schmidt MK, Hogervorst F, van Hien R, Cornelissen S, Broeks A, Adank MA, Meijers H, Waisfisz Q, Hollestelle A, Schutte M, van den Ouweland A, et al.

  • J Clin Oncol. 2016 Aug 10;34(23):2750-60.

2016-09-02

Fig 3. Drug-resistance mutations in patients whose central nervous system (CNS) disease progresses during kinase inhibitor therapy.

Fig 3. Drug-resistance mutations in patients whose central nervous system (CNS) disease progresses during kinase inhibitor therapy.
  • Pentsova EI, Shah RH, Tang J, Boire A, You D, Briggs S, Omuro A, Lin X, Fleisher M, Grommes C, Panageas KS, et al.

  • J Clin Oncol. 2016 Jul 10;34(20):2404-15.

2016-09-06

Fig 2. Protein–protein interaction network revealed that proteins indicative of platinum response were significantly enriched in Ran-GTPase binding, ATP synthesis pathways, and regulation mechanisms of the cell cycle.

Fig 2. Protein–protein interaction network revealed that proteins indicative of platinum response were significantly enriched in Ran-GTPase binding, ATP synthesis pathways, and regulation mechanisms of the cell cycle.
  • Yu KH, Levine DA, Zhang H, Chan DW, Zhang Z, Snyder M

  • J Proteome Res. 2016 Aug 5;15(8):2455-65.

2016-09-07

Fig 4. Transient Activation-Induced Increase in H3K27me3 at Foxp3-Bound Sites.

Fig 4. Transient Activation-Induced Increase in H3K27me3 at Foxp3-Bound Sites.
  • van der Veeken J, Gonzalez AJ, Cho H, Arvey A, Hemmers S, Leslie CS, Rudensky AY

  • Cell. 2016 Aug 11;166(4):977-90.

2016-09-08

Fig 5. Mature human T-cells expressing a third-generation chimeric antigen receptor (CAR) against CD123, or CD123 CAR and inducible caspase 9 (iCasp9) in combination are functional in vitro.

Fig 5. Mature human T-cells expressing a third-generation chimeric antigen receptor (CAR) against CD123, or CD123 CAR and inducible caspase 9 (iCasp9) in combination are functional in vitro.
  • Hübner J, Hoseini SS, Suerth JD, Hoffmann D, Maluski M, Herbst J, Maul H, Ghosh A, Eiz-Vesper B, Yuan Q, Ott M

  • Mol Ther. 2016 Aug;24(7):1216-26.

2016-09-09

Fig 2. Example of hemithoracic pleural intensity-modulated radiation therapy (IMRT) in a patient with (A) a resected and (B) an unresectable tumor.

Fig 2. Example of hemithoracic pleural intensity-modulated radiation therapy (IMRT) in a patient with (A) a resected and (B) an unresectable tumor.
  • Rimner A, Zauderer MG, Gomez DR, Adusumilli PS, Parhar PK, Wu AJ, Woo KM, Shen R, Ginsberg MS, Yorke ED, Rice DC

  • J Clin Oncol. 2016 Aug 10;34(23):2761-8.

2016-09-12

Fig 1. A fateful decision.

Fig 1. A fateful decision.
  • Plusa B, Hadjantonakis AK

  • Nature. 2016 Aug 18;536(7616):281-2.

2016-09-13

Fig 1. Workflow of tumor–germline sequencing.

Fig 1. Workflow of tumor–germline sequencing.
  • Mandelker D

  • Clin Cancer Res. 2016 Aug 15;22(16):3987-8.

2016-09-14

Fig 1. Structure-guided mutagenesis of SmG.

Fig 1. Structure-guided mutagenesis of SmG.
  • Schwer B, Kruchten J, Shuman S

  • RNA. 2016 Sep;22(9):1320-8.

2016-09-15

Fig 4. Two pathways for DNA joint molecule (JM) processing are regulated by phosphorylation and SUMOylation.

Fig 4. Two pathways for DNA joint molecule (JM) processing are regulated by phosphorylation and SUMOylation.
  • Bonner JN, Zhao X

  • Genes (Basel). 2016 Aug 17;7(8).
Open Access button

2016-09-16

Fig 2. Schematics of (A) the chemoenzymatic synthesis of sshuA33-PEG12-TCO and (B) the bioorthogonal approach to pretargeted PET imaging.

Fig 2. Schematics of (A) the chemoenzymatic synthesis of sshuA33-PEG12-TCO and (B) the bioorthogonal approach to pretargeted PET imaging.
  • Cook BE, Adumeau P, Membreno R, Carnazza KE, Brand C, Reiner T, Agnew BJ, Lewis JS, Zeglis BM

  • Bioconjug Chem. 2016 Aug 17;27(8):1789-95.

2016-09-20

Fig 9. Mixed acinar ductal carcinoma.

Fig 9. Mixed acinar ductal carcinoma.
  • Klimstra DS, Adsay V

  • Semin Diagn Pathol. 2016 Sep;33(5):307-18.

2016-09-21

Fig 1. SAR405838 mode of action and determination of VAF threshold for TP53 mutations.

Fig 1. SAR405838 mode of action and determination of VAF threshold for TP53 mutations.
  • Jung J, Lee JS, Dickson MA, Schwartz GK, Le Cesne A, Varga A, Bahleda R, Wagner AJ, Choy E, De Jonge MJ, Light M

  • Nat Commun. 2016 Aug 31;7:12609.
Open Access button

2016-09-22

Fig 1. Structure of MORC3 ATPase-CW cassette in complex with AMPPNP and H3K4me3 peptide.

Fig 1. Structure of MORC3 ATPase-CW cassette in complex with AMPPNP and H3K4me3 peptide.
  • Li S, Yen L, Pastor WA, Johnston JB, Du J, Shew CJ, Liu W, Ho J, Stender B, Clark AT, Burlingame AL

  • Proc Natl Acad Sci U S A. 2016 Aug 30;113(35):E5108-16.

2016-09-23

Fig 1. p28 Mechanism of antitumor action.

Fig 1. p28 Mechanism of antitumor action.
  • Lulla RR, Goldman S, Yamada T, Beattie CW, Bressler L, Pacini M, Pollack IF, Fisher PG, Packer RJ, Dunkel IJ, Dhall G

  • Neuro Oncol (2016) 18 (9): 1319-1325.

2016-09-26

Differences in the diagnosis methods and treatment methods of traditional Chinese medicine and Western Medicine.

Differences in the diagnosis methods and treatment methods of traditional Chinese medicine and Western Medicine.
  • Ye J, Cai X, Yang J, Sun X, Hu C, Xia J, Shen J, Su K, Yan H, Xu Y, Zhang Y

  • Sci Rep. 2016 Aug 31;6:32496.
Open Access button

2016-09-27

Fig 4.  PtdIns(3)P binding to PX domain of SGK3 promotes phosphorylation and activation by PDK1.

Fig 4. PtdIns(3)P binding to PX domain of SGK3 promotes phosphorylation and activation by PDK1.
  • Bago R, Sommer E, Castel P, Crafter C, Bailey FP, Shpiro N, Baselga J, Cross D, Eyers PA, Alessi DR

  • EMBO J. 2016 Sep 1;35(17):1902-22.

2016-09-28

Fig 1. Modeling oncogenic chromosomal rearrangements by genome editing.

Fig 1. Modeling oncogenic chromosomal rearrangements by genome editing.
  • Maddalo D, Ventura A

  • Cancer Res. 2016 Sep 1;76(17):4918-23.

2016-09-29

Fig 4. Interfacial mutants on BNRF1 exhibit reduced subnuclear co-localization with DAXX.

Fig 4. Interfacial mutants on BNRF1 exhibit reduced subnuclear co-localization with DAXX.
  • Huang H, Deng Z, Vladimirova O, Wiedmer A, Lu F, Lieberman PM, Patel DJ

  • Nat Commun. 2016 Sep 1;7:12707.
Open Access button

2016-09-30

Fig 3. Effects of benzyl-4-piperidone compounds on growth and apoptosis in Ewing sarcoma preclinical models.

Fig 3. Effects of benzyl-4-piperidone compounds on growth and apoptosis in Ewing sarcoma preclinical models.
  • Shukla NN, Somwar R, Smith RS, Ambati SR, Munoz S, Merchant MS, D'Arcy P, Wang X, Kobos R, Antczak C, Binder B, Shum D, Radu C, Yang G, Taylor BS, Ng CK, Weigelt B, Khodos I, de Stanchina E, Reis-Filho JS, Ouerfelli O, Linder S1, Djaballah H, Ladanyi M

  • Cancer Res. 2016 Aug 1;76(15):4525-34.